IPCI NEWS: Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Re...
Date : 03/30/2015 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Intellipharmaceutics International Inc. (MM) (IPCI)
Quote : 2.7168 0.0 (0.00%) @ 7:58AM
Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Re...
Intellipharmaceutics International Inc. (MM) (NASDAQ:IPCI)
Intraday Stock Chart
Today : Monday 30 March 2015
Click Here for more Intellipharmaceutics International Inc. (MM) Charts.
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of the product development programs for both its Rexista™ Oxycodone Abuse Deterrent oxycodone hydrochloride extended release tablets and for its Regabatin™ XR once-daily, non-generic extended release version of pregabalin.
Rexista™ Oxycodone XR
Rexista™ Oxycodone XR is a non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required. The formulation is intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently co-administered with alcohol. In addition, when crushed or pulverized and hydrated, the proposed extended release formulation is designed to coagulate instantaneously and entrap the drug in a viscous hydrogel, which is intended to prevent syringing, injecting and snorting.
The Company recently submitted an Investigational New Drug Application ("IND") to the United States Food and Drug Administr
For the company’s offshore drilling segment, revenues from drilling contracts increased by $153.9 million to $499.4 million for the three-month period ended December 31, 2014, compared to $345.5 million for the same period in 2013.
The tanker segment is driving growth.
For the tanker segment, net voyage revenues amounted to $23.9 million for the three-month period ended December 31, 2014, compared to $11.9 million for the same period in 2013. The TCE rate for the tanker fleet stood at $26,003 per day per vessel in the three-month period ended December 31, 2014. This improvement is significant compared to the $12,963-per-day-per-vessel TCE rate in the corresponding period of 2013. The PowerShares DB Oil Fund ETF (DBO) tracks the performance of crude oil.
Looking ahead to 2016, Dryships foresees that the strong tanker market should extend well. Other companies are also seeing a similar outlook for the tanker market.